The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma

BJU International

Volumn 103, Issue 6, 2009, Pages 740-746

  Prestwich, Robin J ^b   Scott, Karen J ^b   Brown, Joanne ^b   Harnden, Patricia ^a   Whelan, Peter ^a   Cartledge, Jon ^a   O'Donnell, Dearbhaile ^d   Pandha, Hardev S ^c   Selby, Peter J ^b   Banks, Rosamund E ^b   Merrick, Alison E ^b   Melcher, Alan A ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d ST JAMES S HOSPITAL   (Ireland)

Author keywords

Adjuvant; Autologous; Renal cell carcinoma; Vaccine

Indexed keywords

CANCER VACCINE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CELL LYSATE; CELL VIABILITY; DENDRITIC CELL; FEMALE; HEALTH SERVICE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOGENICITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; TUMOR BIOPSY; VACCINATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CARCINOMA, RENAL CELL; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGIC METHODS; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGRAM EVALUATION; TISSUE BANKS;

EID: 61349156654     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08113.x     Document Type: Article

References (30)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996 335 : 865 75
2. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987 13 : 665 72
3. Pizzocaro G, Piva L, Di Fronzo G et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer. 5-year Results of a prospective randomized study. J Urol 1987 138 : 1379 81
4. Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003 21 : 3133 40
5. Messing EM, Manola J, Wilding G et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003 21 : 1214 22
6. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 24
7. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 34
8. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005 54 : 187 207
9. Young RC. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? N Engl J Med 1998 338 : 1305 6
10. Nakano O, Sato M, Naito Y et al. Proliferative activity of intratumoral CD8 (+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001 61 : 5132 6
11. Nathan PD, Eisen TG. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol 2002 3 : 89 96
12. Guida M, Colucci G. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? Ann Oncol 2007 18 : vi149 52
13. Ward S, Casey D, Labarthe MC et al. Immunotherapeutic potential of whole tumour cells. Cancer Immunol Immunother 2002 51 : 351 7
14. Merrick A, Diaz RM, O'Donnell D, Selby P, Vile R, Melcher A. Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy. Cancer Immunol Immunother 2008 57 : 897 906
15. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004 363 : 594 9
16. Coppin C. Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma. Cancer Treat Rev 2004 30 : 589 93
17. Galligioni E, Quaia M, Merlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year Results of a prospective randomized study. Cancer 1996 77 : 2560 6
18. Booth C, Harnden P, Trejdosiewicz LK, Scriven S, Selby PJ, Southgate J. Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest 1997 76 : 843 57
19. Lobban ED, Smith BA, Hall GD et al. Uroplakin gene expression by normal and neoplastic human urothelium. Am J Pathol 1998 153 : 1957 67
20. Romani N, Reider D, Heuer M et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996 196 : 137 51
21. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 2003 63 : 4112 8
22. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000 18 : 767 811
23. Matzinger P. An innate sense of danger. Semin Immunol 1998 10 : 399 415
24. Somersan S, Larsson M, Fonteneau JF, Basu S, Srivastava P, Bhardwaj N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 2001 167 : 4844 52
25. Gastl G, Ebert T, Finstad CL et al. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J Urol 1996 155 : 361 7
26. Seliger B, Hammers S, Hohne A et al. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res 1997 3 : 573 8
27. Wszolek MF, Wotkowicz C, Libertino JA. Surgical management of large renal tumors. Nat Clin Pract Urol 2008 5 : 35 46
28. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 2005 54 : 587 98
29. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994 12 : 991 1045
30. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 2006 50 : 34 43